Mediterranean diet, olive oil and cancer

被引:77
作者
Colomer R. [1 ]
Menéndez J.A. [2 ,3 ,4 ]
机构
[1] Department of Medical Oncology, Institut Catala d'Oncologia, Hospital de Girona Dr. Josep Trueta
[2] Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL
[3] Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
[4] Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
关键词
Cancer; erb B-2; Her2; Mediterranean diet; Oleic acid; Olive oil;
D O I
10.1007/s12094-006-0090-0
中图分类号
学科分类号
摘要
Olive oil is an integral ingredient of the «Mediterranean diet» and accumulating evidence suggests that it may have a potential role in lowering the risk of several types of cancers. The mechanisms by which the carcer-preventing effects of olive oil can be performed, however, are not known. We recently hypothesized that a novel molecular explanation concerning the anti-cancer actions of olive oil may relate to the ability of its monounsaturated fatty acid (MUFA) oleic acid (OA; 18:1n-9) to specifically regulate cancer-related oncogenes. Supporting our hypothesis, exogenous suplementation of cultured breast cancer cells with physiological concentrations of OA was found to suppress the overexpression of HER2 (Her-2/neu, erbB-2), a well-characterized oncogene playing a key role in the etiology, progression and response to chemotherapy and endocrine therapy in approximately 20% of breast carcinomas. OA treatment was also found to synergistically enhance the efficacy of trastuzumab, a humanized monoclonal antibody binding with high affinity to the ectodomain (ECD) of the Her2-coded p185HER2 oncoprotein. Moreover, OA exposure significantly diminished the proteolytic cleavage of the ECD of HER2 and, consequently, its activation status, a crucial molecular event that determines both the aggressive behavior and theresponse to trastuzumab of Her2-overexpressing breast carcinomas. Our most recent findings further reveal that OA exposure may suppresses HER2 at the transcriptional level by up-regulating the expression of the Ets protein PEA3 -a DNA-binding protein that specifically blocks HER2 promoter activity-in breast, ovarian and stomach cancer cell lines. This anti-HER2 property of OA offers a previously ously unrecognized molecular mechanism by which olive oil may regulate the malignant behavior of cancer cells. From a clinical perspective, it could provide an effective means of influencing the outcome of Her-2/ neu-overexpressing human carcinomas with poor prognosis. Indeed, OA-induced transcriptional pression of HER2 oncogene may represent a novel genomic explanation linking «Mediterranean diet», olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas. © FESEO 2006.
引用
收藏
页码:15 / 21
页数:6
相关论文
共 70 条
  • [61] Nagata Y., Lan K.H., Zhou X., Et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts transtuzumab resistance in patients, Cancer Cell, 6, pp. 117-127, (2004)
  • [62] Miller K.D., The role of ErbB inhibitors in trastuzumab resistance, Oncologist, 9, SUPPL. 3, pp. 16-19, (2004)
  • [63] Yakes F.M., Chinratanalab W., Ritter C.A., Et al., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action, Cancer Res., 62, pp. 4132-4141, (2002)
  • [64] Carney W.P., Neumann R., Lipton A., Et al., Potential clinical utility of serum HER-2/neu oncoprotein concentration in patients with breast cancer, Clin Chem., 49, pp. 1579-1598, (2003)
  • [65] Hudelist G., Kostler W.J., Attems J., Et al., Her-2/neu-triggered intracellular tyrosine kinase activation: In vivo relevance of lig-and-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment, Br J Cancer, 89, pp. 983-991, (2003)
  • [66] Marchetti P., Natural medicine: A "new frontier" in oncology?, Ann Oncol., 16, pp. 339-340, (2005)
  • [67] Nelson R., Oleic acid suppresses overexpression of ER BB2 oncogene, Lancet Oncol., 6, (2005)
  • [68] Xing X., Wang S.C., Xia W., Et al., The ets protein PEA5 suppresses HER-2/new overexpression and inhibits tumorigenesis, Nat. Med., 6, pp. 189-195, (2000)
  • [69] Wang S.C., Hung M.C., Transcriptional targeting of the HER-2/neu oncogene, Drugs Today (Barc), 36, pp. 835-843, (2000)
  • [70] Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M., Insulin-like growth factor-1 receptor signaling and resistance to transtuzumab (Herceptin), J Natl Cancer Inst., 93, pp. 1852-1857, (2001)